257 Results for "

JNJ 28431754-d6

" in MedChemExpress (MCE) Product Catalog:
Products (257)

257 Results for "JNJ 28431754-d6" in MCE Product Catalog:

47
47 Publications Verification
Cat. No.: HY-10451
CAS No.: 842133-18-0
Purity:  99.70%
Synonyms: JNJ 28431754
Target:  

SGLT

Research Areas:  

Metabolic Disease Cancer

Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .
loading...
    loading...
47
47 Publications Verification
Cat. No.: HY-I0383
CAS No.: 928672-86-0
Synonyms: JNJ 28431754 hemihydrate
Target:  

SGLT

Research Areas:  

Metabolic Disease Cancer

Canagliflozin hemihydrate (JNJ28431754 hemihydrate) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .
loading...
    loading...
40
40 Cited Publications
Cat. No.: HY-18708
CAS No.: 1346242-81-6
Synonyms: JNJ-42756493
Target:  

FGFR Apoptosis

Research Areas:  

Cancer

Erdafitinib (JNJ-42756493) is a potent and orally available FGFR family inhibitor; inhibits FGFR1/2/3/4 with IC50s of 1.2, 2.5, 3.0 and 5.7 nM, respectively.
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-15433
CAS No.: 875320-29-9
Purity:  99.71%
Synonyms: JNJ-26481585
Target:  

HDAC Autophagy

Research Areas:  

Inflammation/Immunology Cancer

Quisinostat (JNJ-26481585) is a potent and orally active pan-HDAC inhibitor (HDACi), with IC50 values ranging from 0.11 nM to 0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11. Quisinostat has a broad spectrum antitumoral activity . Quisinostat can induce autophagy in neuroblastoma cells .
loading...
    loading...
18
18 Cited Publications
Cat. No.: HY-15433A
CAS No.: 875320-31-3
Purity:  99.05%
Synonyms: JNJ-26481585 dihydrochloride
Target:  

HDAC Autophagy

Research Areas:  

Inflammation/Immunology Cancer

Quisinostat dihydrochloride (JNJ-26481585 dihydrochloride) is an orally active, potent pan-HDAC inhibitor with IC50s of 0.11 nM, 0.33 nM, 0.64 nM, 0.46 nM, and 0.37 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11, respectively. Quisinostat dihydrochloride has a broad spectrum antitumoral activity. Quisinostat dihydrochloride can induce autophagy in neuroblastoma cells .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-101564
CAS No.: 2086772-26-9
Purity:  99.78%
Synonyms: JNJ-64619178
Research Areas:  

Cancer

Onametostat (JNJ-64619178) is a selective, orally active and pseudo-irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC50 of 0.14 nM. Onametostat has potent activity in lung cancer .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-P9915
CAS No.: 945721-28-8
Synonyms: Anti-Human CD38, Human Antibody; HuMax-CD38; JNJ-54767414

Target:  

CD38 ADC Antibodies

Research Areas:  

Inflammation/Immunology Cancer

Daratumumab (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab has anti-multiple myeloma (MM) effect. Daratumumab impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition .
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-19568
CAS No.: 944118-01-8
Synonyms: ASP015K; JNJ-54781532
Target:  

JAK

Research Areas:  

Inflammation/Immunology

Peficitinib (ASP015K) is an orally active JAK inhibitor, with IC50s of 3.9, 5.0, 0.7 and 4.8 nM for JAK1, JAK2, JAK3 and Tyk2, respectively .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-103482
CAS No.: 315705-75-0
Purity:  99.80%
Target:  

MMP

Research Areas:  

Cancer

JNJ0966 is a highly selective MMP-9 zymogen inhibitor with an IC50 of 440 nM.
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-50683
CAS No.: 943540-75-8
Target:  

c-Met/HGFR

Research Areas:  

Metabolic Disease Cancer

JNJ-38877605 is an orally active ATP-competitive inhibitor of c-Met with an IC50 of 4 nM, 600-fold selective for c-Met than 200 other tyrosine and serine-threonine kinases . JNJ-38877605 inhibits c-Met phosphorylation and regulates lipid accumulation. JNJ-38877605 can be used for tumor and metabolic disease reseach .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-101418
CAS No.: 1428327-31-4
Purity:  99.79%
Target:  

P2X Receptor

Research Areas:  

Neurological Disease

JNJ-47965567 is a centrally permeable, high-affinity, selective P2X7 antagonist, with pKis of 7.9 and 8.7 for human and rat P2X7, respectively. JNJ-47965567 can be used to probe the role of central P2X7 in rodent models of CNS pathophysiology .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-149143
CAS No.: 2765255-93-2
Purity:  98.82%
Target:  

TRP Channel

Research Areas:  

Inflammation/Immunology

JNJ-28583113 is an TRPM2 antagonist with brain permeability. JNJ-28583113 inhibits TRPM2 blocked phosphorylation of GSK3α and β subunits. JNJ-28583113 protects cells from oxidative stress induced cell death. JNJ-28583113 also suppresses cytokine release in response to pro-inflammatory stimuli in microglia .
loading...
    loading...
5
5 Cited Publications
Cat. No.: HY-112180
CAS No.: 1383450-81-4
Purity:  ≥98.0%
Synonyms: JNJ-678; JNJ-53718678
Target:  

RSV

Research Areas:  

Infection

Rilematovir (JNJ-678) is a novel fusion protein inhibitor. Rilematovir has the potential for respiratory syncytial virus (RSV) research.
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-109012
CAS No.: 1293281-49-8
Purity:  99.86%
Synonyms: JNJ-42847922
Seltorexant (JNJ-42847922) is an orally active, high-affinity, and selective orexin-2 receptor (OX2R) antagonist (pKi values of 8.0 and 8.1 for human and rat OX2R). Seltorexant (JNJ-42847922) crosses the blood-brain barrier and quickly occupies OX2R binding sites in the rat brain .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-10329
CAS No.: 443797-96-4
Purity:  99.91%
Research Areas:  

Cancer

JNJ-7706621 is a potent aurora kinase inhibitor, and also inhibits CDK1 and CDK2, with IC50s of 9 nM, 3 nM, 11 nM, and 15 nM for CDK1, CDK2, aurora-A and aurora-B, respectively .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-109012A
CAS No.: 1293284-49-7
Purity:  99.90%
Synonyms: JNJ-42847922 hydrochloride
Seltorexant hydrochloride (JNJ-42847922 hydrochloride) is an orally active, high-affinity, and selective OX2R antagonist (pKi values of 8.0 and 8.1 for human and rat OX2R). Seltorexant hydrochloride crosses the blood-brain barrier and quickly occupies OX2R binding sites in the rat brain .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-Q36392
CAS No.: 326923-09-5
Target:  

Histone Demethylase

Research Areas:  

Cancer

JNJ-9350, a chemical probe, is an inhibitor of spermine oxidase (SMOX) with an IC50 value of 0.01 μM. JNJ-9350 also inhibits polyamine oxidase (PAO) with an IC50 value of 0.79 μM. JNJ-9350 can be used for the research of cancer .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-123857
CAS No.: 2166558-11-6
Purity:  99.82%
JNJ-55308942 is a high-affinity, selective, brain-penetrant P2X7 functional antagonist (hP2X7: IC50=10 nM, Ki=7.1 nM; rP2X7: IC50=15 nM, Ki=2.9 nM). JNJ-55308942 is orally bioavailable, binds to brain P2X7 and blocks IL-1β release from adult rodent brain .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-109168
CAS No.: 1638266-40-6
Purity:  99.24%
Synonyms: JNJ-6379; JNJ-56136379
Target:  

HBV DNA/RNA Synthesis

Research Areas:  

Infection

Bersacapavir (JNJ-6379) is an HBV capsid assembly modulator. Bersacapavir exerts a dual mechanism of action against both early and late stages of HBV infection by forming complete genome-free empty capsids and inhibiting de novo synthesis of cccDNA. Bersacapavir inhibits HBV replication. Bersacapavir can be used in the research of hepatitis B .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-109086
CAS No.: 1142363-52-7
Purity:  98.80%
Synonyms: JNJ-40346527; JNJ-527
Target:  

c-Fms

Edicotinib (JNJ-40346527) is a potent, selective, brain penetrant and orally active colony-stimulating factor-1 receptor (CSF-1R) inhibitor with an IC50 of 3.2 nM. Edicotinib exhibits less inhibitory effects on KIT and FLT3 with IC50 values of 20 nM and 190 nM, respectively . Edicotinib limits microglial expansion and attenuates microglial proliferation and neurodegeneration in mice. Edicotinib has the potential for Alzheimer’s disease and rheumatoid arthritis research .
loading...
    loading...